ArticleJournal of oncology practice2017
Fanning the Flames of Cancer Chemoresistance: Inflammation and Anticancer Therapy.
Article in Journal of oncology practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Prognostic significance of systemic pan-immune-inflammation value in locally advanced cervical cancer.Frontiers in oncology · 2024Article
- Predicting monotherapy resistance risk in patients with low-risk gestational trophoblastic neoplasia: integration of the systemic immune-inflammation index and the prognostic nutritional index.Frontiers in oncology · 2024Article
- Predicting Chemotherapy Resistance in Gestational Trophoblastic Neoplasia: Ratio of Neutrophils, Lymphocytes, Monocytes, and Platelets.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Article
- The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.Journal of leukocyte biology · 2020Review
- Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.Pharmacology & therapeutics · 2019Review
- Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy.Cancer management and research · 2019Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.